Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Company Drug

Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine

Fineline Cube Mar 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...

Company Drug

AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China

Fineline Cube Mar 17, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...

Company Deals

Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development

Fineline Cube Mar 17, 2023

Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...

Company Drug

NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216

Fineline Cube Mar 17, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for...

Company Drug

Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China

Fineline Cube Mar 17, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Company Drug

Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Mar 17, 2023

China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from...

Company Deals

Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab

Fineline Cube Mar 17, 2023

US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology...

Policy / Regulatory

Beijing Initiates Volume-Based Procurement for Ophthalmology and Orthopedics Medical Consumables

Fineline Cube Mar 17, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification regarding the volume-based procurement (VBP)...

Company Drug

Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension

Fineline Cube Mar 17, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...

Company Drug

RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor

Fineline Cube Mar 17, 2023

China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...

Company Deals

Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms

Fineline Cube Mar 17, 2023

China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with...

Company Drug

ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors

Fineline Cube Mar 16, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Deals

ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705

Fineline Cube Mar 16, 2023

Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...

Company Medical Device

Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications

Fineline Cube Mar 16, 2023

Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...

Company

Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services

Fineline Cube Mar 16, 2023

Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB...

Company

Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab

Fineline Cube Mar 16, 2023

China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product...

Company

CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees

Fineline Cube Mar 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB...

Company Drug

Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study

Fineline Cube Mar 16, 2023

Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the...

Posts pagination

1 … 540 541 542 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.